Creator: Help Dementia Editorial Team
Published: 2026-05-29T06:38:51

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Patients sits at the center of this dementia and brain health question.

Patients and families facing Alzheimer’s disease now have more treatment options than ever before, but these emerging therapies work differently than traditional medications and come with important tradeoffs. As of 2026, there are three FDA-approved disease-modifying drugs that can slow cognitive decline by targeting amyloid buildup in the brain—Leqembi, Kisunla, and the newer maintenance formulations of Leqembi. However, these are not cures, they work best in early stages of disease, and they require ongoing monitoring with brain imaging to watch for side effects. Understanding what these treatments actually do, who they help most, what they cost, and what’s coming in the research pipeline is essential for making informed decisions about your care.

The landscape of Alzheimer’s treatment has shifted fundamentally. For decades, patients had only symptomatic medications like donepezil that temporarily masked memory loss without slowing the underlying disease. Now, for the first time, science has proven that clearing amyloid protein from the brain can slow cognitive decline—a breakthrough that’s driving 158 different drugs through development, with 73 percent targeting the disease mechanisms themselves rather than just symptoms. But this progress comes with a new set of questions: Are these drugs right for me? How much will they cost? What are the risks? What should I expect in the coming years? This article walks through what emerging Alzheimer’s therapies are, what the evidence shows, the practical realities of access and cost, and what the research pipeline suggests about future treatment options.

FDA-Approved Therapies Now Available and What They Actually Do
Treatment Costs and the Insurance Coverage Puzzle
The Massive Pipeline of Drugs in Development
Prevention Trials and Treating Alzheimer’s Before Symptoms Appear
Side Effects, Monitoring, and the Reality of Living on These Therapies
Combination Therapies and Emerging Multi-Target Approaches
Looking Forward—What the Next Few Years Will Likely Bring
Conclusion

FDA-Approved Therapies Now Available and What They Actually Do

Three disease-modifying drugs have FDA approval as of 2026, all targeting amyloid protein accumulation in the brain. Leqembi (lecanemab) received full FDA approval in July 2023 and was the first therapy proven to slow cognitive decline by clearing amyloid. Kisunla (donanemab) followed with FDA approval on July 2, 2024, also for mild cognitive impairment and mild dementia stages. Both are given by infusion or injection and work by binding to amyloid beta plaques and helping the immune system remove them. The clinical benefit from these drugs is real but modest. A major Cochrane review from April 2026 found the effect on cognition is “trivial” when measured over shorter periods, but the key insight is that benefit accumulates over three to four years for patients who stay on treatment.

Think of it this way: while a patient on Leqembi might decline 25 percent over 18 months, without the drug they might decline 35 percent in the same timeframe. It’s slowing, not stopping, and the advantage compounds. This matters most for people in early stages—those with mild cognitive impairment or mild dementia—because the drug works on amyloid that’s already accumulated. Leqembi has expanded options since 2023. The original intravenous infusion every two weeks remains the standard, but a monthly IV maintenance option was approved in January 2025, and in August 2025 the FDA approved Leqembi IQLIK™, a subcutaneous weekly autoinjector. This means patients who found the original schedule burdensome now have flexibility. However, all these formulations require ongoing monitoring with PET scans or amyloid biomarker blood tests to watch for amyloid-related imaging abnormalities (ARIA)—brain changes that can occur as amyloid clears, potentially causing swelling or microhemorrhages.

FDA-Approved Therapies Now Available and What They Actually Do

Treatment Costs and the Insurance Coverage Puzzle

The financial reality of these drugs is a major barrier for many patients. Leqembi costs approximately $26,500 annually, but the true out-of-pocket cost depends on insurance. Beyond the drug itself, you’ll need hundreds to thousands of dollars more for required brain imaging and monitoring. Kisunla prices differently: $12,522 for six months of treatment, scaling to up to $48,896 for 1.5 years of therapy, averaging around $32,000 annually. For families already stretched thin by caregiving expenses, this is significant. Medicare now covers both Leqembi and Kisunla, which was a turning point for older patients who have coverage through the federal program.

However, many private insurers continue to deny coverage, citing insufficient benefit justification—meaning they weigh the modest cognitive slowing against the cost and conclude the value isn’t there. Some insurers require prior authorization or demand that patients have already failed other treatments first. This creates a patchwork where your ability to access these drugs depends heavily on your insurance plan. A patient with good coverage might pay only a copay, while another with Medicare Advantage might face denial or high out-of-pocket costs. There’s also an equity dimension worth considering. These are expensive, time-intensive treatments requiring regular clinic visits and brain imaging. Patients with transportation barriers, those in rural areas with limited neurological care, and those without insurance face significant obstacles to access, even if they’re willing to take on the side effect risks.

The Massive Pipeline of Drugs in Development

The drug development pipeline tells a story of explosive growth in Alzheimer’s research. As of 2026, there are 158 drugs in active development, with 73 percent being disease-targeted therapies—meaning they aim at the underlying mechanisms rather than just treating symptoms. This is unprecedented for Alzheimer’s. Eight Phase 3 clinical trials will reach their primary completion dates in 2026 alone, and 29 Phase 2 trials will be completed the same year, suggesting we’ll have new efficacy data and possibly new FDA approvals within months to a few years. The diversity of approaches in development is noteworthy. While amyloid-targeting drugs like Leqembi and Kisunla were the first to reach approval, researchers are now systematically attacking other disease pathways.

Tau-targeted therapies are in multiple forms—monoclonal antibodies, vaccines, antisense oligonucleotides, and small molecules—all being tested as standalone treatments or in combination with amyloid-targeting drugs. The Alzheimer’s Tau Platform (ATP) trial, for example, is evaluating tau-directed therapies alone or combined with donanemab in people aged 50-80 with preclinical or early prodromal Alzheimer’s disease. This platform approach allows researchers to test multiple tau strategies simultaneously, accelerating the timeline. What this means for patients now is that if you’re considering a treatment decision, the landscape will likely look very different in two to three years. Talking with your neurologist about the possibility of enrolling in clinical trials, rather than waiting only for FDA-approved options, might give you access to newer approaches sooner. But it also means being cautious about decisions made based on today’s options—new information arrives frequently in this field.

The Massive Pipeline of Drugs in Development

Prevention Trials and Treating Alzheimer’s Before Symptoms Appear

One of the most significant shifts happening in Alzheimer’s research is the move toward prevention. The AHEAD Study, an ongoing Phase 3 clinical trial that began in July 2020, is testing lecanemab in clinically normal individuals who have intermediate or elevated amyloid brain levels but no cognitive symptoms yet. The idea is radical: treat Alzheimer’s disease before anyone even knows they have it, based on brain imaging or blood biomarkers showing amyloid accumulation. If prevention trials read out positively over the next two to three years, the entire Alzheimer’s treatment paradigm would shift.

Instead of waiting for memory loss to develop, then offering treatment, the field would move toward identifying people at risk through biomarker screening and treating them preventively. This could delay symptom onset by years or even prevent it entirely. However, this also raises difficult questions: Should asymptomatic people take drugs for years based on a biomarker alone? What are the long-term side effects of treating people who might never have developed symptoms? How do you screen millions of people for amyloid to find those who need treatment? For patients and families, the practical implication is this: if you’re cognitively normal but concerned about Alzheimer’s risk—perhaps you have a family history—discussing biomarker screening with your doctor might become standard soon. Clinical trials are actively recruiting, and participating gives access to cutting-edge therapies before FDA approval. But we won’t have clear answers about the risk-benefit of prevention until the data comes in.

Side Effects, Monitoring, and the Reality of Living on These Therapies

The most serious side effect of amyloid-targeting drugs is amyloid-related imaging abnormality (ARIA), which can manifest as brain swelling (ARIA-E) or microhemorrhages (ARIA-H). In clinical trials, ARIA occurs in roughly 20-30 percent of patients, though most cases are asymptomatic—detected only on brain imaging. Symptomatic cases are rarer but serious: patients report headache, confusion, vision changes, or nausea when significant swelling occurs. ARIA-related microhemorrhages can occasionally lead to larger bleeding events, though this is uncommon. This means being on these drugs isn’t like taking a daily pill. You need regular clinical monitoring—infusion appointments or injections every one to four weeks depending on the drug and formulation, combined with periodic brain imaging to catch ARIA before it becomes symptomatic.

For a 72-year-old with mild cognitive impairment, this might mean monthly visits to the infusion center, quarterly or biannual PET scans or amyloid PET imaging, and blood work. It’s a commitment. If ARIA develops, your doctor might pause treatment, manage the swelling with steroids, and restart once it resolves—or discontinue entirely if it’s severe. For patients considering these treatments, an honest conversation with your neurologist should cover: What is your tolerance for the monitoring commitment? Do you have transportation to regular appointments? Are you comfortable with brain imaging procedures? Some patients find the monitoring reassuring—they’re seeing their doctor regularly, getting neurological assessments, tracking biomarkers. Others find it burdensome. There’s no universally right answer; it depends on your values and circumstances. But pretending these drugs are simple interventions would be misleading.

Side Effects, Monitoring, and the Reality of Living on These Therapies

Combination Therapies and Emerging Multi-Target Approaches

The next frontier in Alzheimer’s treatment is combining drugs that target different disease mechanisms. Rather than treating just amyloid or just tau or just neuroinflammation, the idea is to hit multiple pathways simultaneously. Trials are already underway testing amyloid-targeting drugs like donanemab in combination with tau-targeting therapies, based on evidence that both pathologies contribute to Alzheimer’s neurodegeneration.

These combination approaches make biological sense—Alzheimer’s isn’t caused by one protein accumulating in isolation; it’s a complex cascade involving amyloid, tau, neuroinflammation, and vascular changes. A patient might benefit more from addressing two or three of these pathways simultaneously rather than targeting one. The challenge is that adding more drugs means more side effects, more monitoring, higher costs, and more complexity. Trials in 2026 will begin clarifying which combinations work, which are safe, and which justify the added burden.

Looking Forward—What the Next Few Years Will Likely Bring

By 2028 or 2029, we’ll likely have several new FDA-approved therapies, probably including tau-targeted drugs and possibly combination approaches. Prevention trials should have reported results, giving us data on whether treating asymptomatic amyloid-positive people delays symptom onset. Blood-based biomarkers for amyloid, tau, and other pathologies will probably be refined further, making screening easier and less expensive than brain imaging.

The treatment landscape will expand significantly from the three options available today. What’s less certain is whether these developments will translate into truly transformative outcomes for patients or remain incremental improvements in slowing decline. A 35 percent slowing of cognitive decline—the benefit observed with current drugs—is meaningful for some patients but disappointing for others hoping for stabilization or reversal. The drugs that emerge from today’s pipeline will face the same scrutiny: How much benefit? At what cost? For whom? And crucially, will the healthcare system and insurance coverage adapt to make these therapies accessible, or will access remain dependent on geography, insurance type, and ability to pay?.

Conclusion

Patients should know that Alzheimer’s treatment has genuinely changed—there are now FDA-approved drugs that slow cognitive decline by targeting the disease itself, not just treating symptoms. Leqembi and Kisunla, along with emerging therapies in clinical trials, represent a fundamental shift from purely symptomatic care to disease modification. However, these aren’t cures, they work best in early disease stages, they come with side effects requiring monitoring, and they cost tens of thousands of dollars annually.

The future is moving toward earlier intervention—possibly treating asymptomatic people at risk before symptoms develop—and toward combination therapies that target multiple disease pathways simultaneously. For anyone facing an Alzheimer’s diagnosis or concerned about risk, the immediate steps are: get a clear diagnosis with biomarker testing if possible, discuss your specific situation with a neurologist who specializes in cognitive disorders, understand your insurance coverage and the monitoring commitment these drugs require, and consider clinical trial participation as an option for access to emerging therapies. The field is moving fast, and the right choice today might look different in two years. Staying informed and in dialogue with your care team is essential.